APA (7th ed.) Citation

Wang, C., Zhou, C., Hou, S., Fan, W., Qian, W., Ren, Y., . . . Guo, Y. (2026). A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007). Pharmaceuticals (14248247), 19(5), 724. https://doi.org/10.3390/ph19050724

Chicago Style (17th ed.) Citation

Wang, Chenguang, et al. "A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007)." Pharmaceuticals (14248247) 19, no. 5 (2026): 724. https://doi.org/10.3390/ph19050724.

MLA (9th ed.) Citation

Wang, Chenguang, et al. "A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007)." Pharmaceuticals (14248247), vol. 19, no. 5, 2026, p. 724, https://doi.org/10.3390/ph19050724.